GRP logo
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report-Part IV

The citation for this report is:
Mullins CD, Seal B, Seoane-Vazquez E, et al. Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report-Part IV. Value Health 2010;13:18-24.

Task Force Leadership Group
C. Daniel Mullins PhD, Medicare Subgroup Chair & Professor and Chair, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA
Brian Seal RPh, MBA, PhD, Medicaid Subgroup Chair & Senior-Director Health Outcomes Research, Internal Medicine and Oncology, Sanofi-Aventis Pharmaceuticals, Bridgewater, NJ, USA
Enrique Seoane-Vazquez PhD, Assistant Professor, College of Pharmacy & College of Public Health, The Ohio State University, Columbus, OH, USA
Jayashri Sankaranarayanan PhD, Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA
Carl Asche PhD, Associate Professor, University of Utah, Salt Lake City, UT, USA
Ravishankar Jayadevappa PhD, Research Assistant Professor, University of Pennsylvania, Philadelphia, PA, USA
Won Chan Lee PhD, Principal of Health Economics, IMS Health Inc, Falls Church, VA, USA
Dorothy Romanus RPh, MSc, Project Manager, Dana Farber Cancer Institute, Boston, MA, USA
Junling Wang PhD, Assistant Professor, Department of Pharmaceutical Sciences & Adjunct Assistant Professor, Department of Clinical Pharmacy, University of Tennessee College of Pharmacy, Memphis, TN, USA

For recommendations on how drug costs should be measured for cost-effectiveness analysis from other key analytic perspectives, please refer to the following reports:

FINAL REPORT
The Drug Cost Standards Task Force presented their reports including responses to member comments during an open forum at ISPOR’s 14th Annual International Meeting in Orlando, FL in May 2009.  The task force’s forum presentation can be viewed at: Forum Presentation


ISPOR Good Practices For Outcomes Research Index